Travoprost/timolol: Difference between revisions
CSV import |
CSV import |
||
| Line 29: | Line 29: | ||
__NOINDEX__ | __NOINDEX__ | ||
{{No image}} | {{No image}} | ||
__NOINDEX__ | |||
Latest revision as of 01:35, 18 March 2025
Travoprost/timolol is a combination medication used in the treatment of glaucoma and ocular hypertension. It contains two active ingredients: travoprost, a prostaglandin analogue, and timolol, a non-selective beta blocker.
Etymology[edit]
The name "travoprost" is derived from the chemical name for the compound, which is a prostaglandin F2α analogue. The name "timolol" is derived from the chemical name for the compound, which is a non-selective beta-adrenergic receptor blocker.
Pharmacology[edit]
Travoprost/timolol works by reducing the pressure in the eye. Travoprost increases the outflow of aqueous humor, the fluid in the eye, while timolol decreases the production of this fluid.
Indications[edit]
Travoprost/timolol is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues.
Side Effects[edit]
Common side effects of travoprost/timolol include ocular hyperemia (red eyes), decreased visual acuity, eye discomfort, foreign body sensation, and dry eye. Systemic side effects can occur, particularly with the timolol component, and can include bradycardia, hypotension, and bronchospasm.
Contraindications[edit]
Travoprost/timolol is contraindicated in patients with reactive airway disease, including asthma or a history of asthma, and severe chronic obstructive pulmonary disease. It is also contraindicated in patients with sinus bradycardia, second or third degree atrioventricular block, overt cardiac failure, and cardiogenic shock.


